Lou Reese Acquires 4,807 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) Stock

Vaxxinity, Inc. (NASDAQ:VAXXGet Rating) Chairman Lou Reese bought 4,807 shares of the stock in a transaction on Wednesday, April 27th. The shares were bought at an average price of $3.58 per share, for a total transaction of $17,209.06. Following the purchase, the chairman now directly owns 51,616,366 shares in the company, valued at approximately $184,786,590.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ VAXX opened at $3.77 on Friday. Vaxxinity, Inc. has a 52 week low of $3.04 and a 52 week high of $22.77. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.08. The company’s 50-day simple moving average is $4.16.

Vaxxinity (NASDAQ:VAXXGet Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.13). Sell-side analysts forecast that Vaxxinity, Inc. will post -1.69 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Prime Movers Lab LLC purchased a new stake in Vaxxinity in the 4th quarter worth approximately $91,020,000. Adage Capital Partners GP L.L.C. purchased a new stake in Vaxxinity in the 4th quarter worth approximately $5,619,000. Goldman Sachs Group Inc. purchased a new stake in Vaxxinity in the 4th quarter worth approximately $1,240,000. Millennium Management LLC purchased a new stake in Vaxxinity in the 4th quarter worth approximately $489,000. Finally, Geode Capital Management LLC purchased a new stake in Vaxxinity during the 4th quarter valued at approximately $382,000.

VAXX has been the topic of several research analyst reports. Evercore ISI began coverage on shares of Vaxxinity in a research note on Wednesday. They set an “in-line” rating on the stock. Zacks Investment Research lowered shares of Vaxxinity from a “hold” rating to a “sell” rating in a research report on Thursday, April 7th.

About Vaxxinity (Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Recommended Stories

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.